BioTech: Accelerating Innovation in Healthcare


​​As the race to save the world from the COVID-19 pandemic barrels on, and teams around the globe work tirelessly to develop effective therapeutics and vaccines, we have all become acutely aware of the potential for new breakthroughs in the biosciences. Whatare we learning from this global effort and how can we accelerate the delivery of new drugs and vaccines to fight current and future diseases more effectively? The answer will likely come from advances initiated by biotech start-ups, aided by new data processing and artificial intelligence.

In this new episode of Samsung’s “The Next Wave” interview series, Young Sohn, Samsung’s President and Chief Strategy Officer, speaks with Rafaèle Tordjman, President and Founder of Jeito Capital, an investment fund dedicated to biotechnology and biopharmaceuticals, about how to boost research in healthcare by providing long-term support to start-ups and technology.


Rafaèle Tordjman

Founder and CEO of Jeito Cap

​Rafaèle Tordjman is the founder and CEO of Jeito capital, a patient benefit-driven biotech and biopharma fund. With the help of a very strong background as an hemato-oncologist and after 17 years at Sofinnova, Tordjman decided to launch Jeito Capital in 2018. Closing at $200 million earlier this year and aiming to reach $500 million by the end of 2020, this thriving first-time fund is a testimony to the team’s successful methods. 

Tordjman shares her thoughts on how to build a solid entrepreneur-investor partnership.​